Inhibrx Biosciences vs Outlook Therapeutics
INBX and OTLK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INBX and OTLK compare
Inhibrx Biosciences is the larger company, worth 12 times as much as Outlook Therapeutics ($1.1B against $87.8M).
Outlook Therapeutics scores higher on the StockData Score (4 against 1 for Inhibrx Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INBX | OTLK |
|---|---|---|
| Size and price | ||
| Market cap | $1.1B | $87.8M |
| Share price | $74.18 | $0.361 |
| Change, 1 year | −6.3% | −77.0% |
| Change, 5 years | 93.5% | −98.7% |
| Beta (5Y) | 2.16 | 3.72 |
| Employees | 110 | 17 |
| StockData Score | ||
| Total score | 1 | 4 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| FCF yield | −12.2% | – |
| Growth | ||
| Revenue growth, 5Y average | −36.8% | – |
| Financial health | ||
| Interest coverage | −5.9× | – |
| Current ratio | 7.58 (better) | 0.81 |
| Altman Z-score | −1.02 (better) | −40.77 |
| Piotroski F-score | 1 | 1 |
| Dividends and buybacks | ||
| Buyback yield | – | −62.3% |
| Shareholder yield | 0.00% (better) | −62.3% |
| Ownership | ||
| Held by institutions | 97.4% | 8.4% |
| Held by insiders | 35.4% | 28.5% |
| Insider net buying, 12 months | $6.1M | $7.9M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 35.7% | 20.4% |
Go deeper
- INBX stock overview
- INBX income statement
- INBX valuation and score
- OTLK stock overview
- OTLK income statement
- OTLK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.